Citations Appearing in 2003

  1. Acosta, E.P. and J.R. King. Methods for integration of pharmacokinetic and phenotypic information in the treatment of infection with human immunodeficiency virus. Clinical Infectious Diseases 36(3):373-377, 2003.
  2. Acosta, E.P. and H.H. Balfour Jr. Intermittent administration of high-dose stavudine to nucleoside-experienced individuals. Journal of Acquired Immune Deficiency Syndromes 33(3):343-348, 2003.
  3. Andersen, K.E. and M. Højbjerre. A population-based Bayesian approach to the minimal model of glucose and insulin homeostasis. Statistics in Medicine 24(15):2381-2400, 2003.
  4. Beran, M., S. O’Brien, D.A. Thomas, H.T. Tran, J.E. Cortes-Franco, F. Giles, E. Estey and H.M. Kantarjian. Phase I study of oral topotecan in hematological malignancies. Clinical Cancer Research 9(11):4084-4091, 2003.
  5. Callegari, T., A. Caumo and C. Cobelli. Bayesian two-compartment and classic single-compartment minimal models: comparison on insulin modified IVGTT and effect of experiment reduction. IEEE Transactions on Biomedical Engineering 50(12):1301-1309, 2003.
  6. DiCenzo, R., M. Shelton, K. Jordan, C. Koval, A. Forrest, R. Reichman and G. Morse. Coadministration of milk thistle and indinavir in healthy subjects. Pharmacotherapy 23(7):866-870, 2003.
  7. DiCenzo, R., A. Forrest, J.C. Slish, C. Cole and R. Guillet. A gentamicin pharmacokinetic population model and once-daily dosing algorithm for neonates. Pharmacotherapy 23(5):585-591, 2003.
  8. DiCenzo, R., A. Forrest, K.E. Squires, S.M. Hammer, M.A. Fischl, H.L. Wu, R. Cha and G.D. Morse. Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects. Antimicrobial Agents and Chemotherapy 47(6):1929-1935, 2003.
  9. Drusano, G.L. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clinical Infectious Diseases 36(s1):S42-S50, 2003.
  10. Dutta, S., J.C. Cloyd, G.R. Granneman and S.D. Collins. Oral/intravenous maintenance dosing of valproate following intravenous loading: a simulation. Epilepsy Research 53(1-2):29-38, 2003.
  11. Edick, M.J., A. Gajjar, H.H. Mahmoud, M.E.C. van de Poll, P.L. Harrison, J.C. Panetta, G.K. Rivera, R.C. Ribeiro, J.T. Sandlund, J.M. Boyett, C.H. Pui and M.V. Relling. Pharmacokinetics and pharmacodynamics of oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia. Journal of Clinical Oncology 21(7):1340-1346, 2003.
  12. Esteva, F.J., E. Rivera, M. Cristofanilli, V. Valero, M. Royce, A. Duggal, P. Colucci, R. DeJager and G.N. Hortobagyi. A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma. Cancer 98(5):900-907, 2003.
  13. Faessel, H.M., H.K. Slocum, Y.M. Rustum and W.R. Greco. Thymidine and hypoxanthine protection patterns of the folic acid-enhanced synergies for combinations of trimetrexate plus a polyglutamylatable inhibitor of purine or thymidylate synthesis against human ileocecal HCT-8 cells. International Journal of Oncology 23(2):401-409, 2003.
  14. Forouzesh, B., C.H. Takimoto, A. Goetz, S. Diab, L.A. Hammond, L. Smetzer, G. Schwartz, R. Gazak, J.T. Callaghan, D.D. Von Hoff and E.K. Rowinsky. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies. Clinical Cancer Research 9(15):5540-5549, 2003.
  15. Frost, B.M., G. Lonnerholm, P. Koopmans, J. Abrahamsson, M. Behrendtz, A. Castor, E. Forestier, D.R.A. Uges and S.S.N. de Graaf. Vincristine in childhood leukaemia: no pharmacokinetic rationale for dose reduction in adolescents. Acta Paediatrica 92(5):551-557, 2003.
  16. Garrison, M.A., L.A. Hammond, C.E. Geyer, G. Schwartz, A.W. Tolcher, L. Smetzer, J.A. Figueroa, M. Ducharme, J. Coyle, C.H. Takimoto, R.L. De Jager and E.K. Rowinsky. A phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies. Clinical Cancer Research 9(7):2527-2537, 2003.
  17. Gastl, G. and C. Dittrich. Standard operating procedures for clinical trials of the CESAR Central European Society for Anticancer Drug Research – EWIV – Preface. Onkologie 26:IX-+ Suppl., 2003.
  18. Gubala, W. and D. Zuba. Gender difference in the pharmacokinetics of ethanol in saliva and blood after oral ingestion. Polish Journal of Pharmacology 55:639-644, 2003.
  19. Hussain, M.M., H. Kotz, L. Minasian, A. Premkumar, G. Sarosy, E. Reed, S.P. Zhai, S.M. Steinberg, M. Raggio, V.K. Oliver, W.D. Figg and E.C. Kohn. Phase II trial of carboxyamidotriazole in patients with relapsed epithelial ovarian cancer. Journal of Clinical Oncology 21(23):4356-4363, 2003.
  20. Jin, J.Y., R.R. Almon, D.C. Dubois and W.J. Jusko. Modeling of corticosteroid pharmacogenomics in rat liver using gene microarrays. Journal Of Pharmacology and Experimental Therapeutics 307(1):93-109, 2003.
  21. Jonsson, S. and M.O. Karlsson. A rational approach for selection of optimal covariate-based dosing strategies. Clinical Pharmacology and Therapeutics 73(1):7-19, 2003.
  22. Joseph, E., J.L. Eiseman, D.S. Hamilton, H.B. Wang, H. Tak, Z.B. Ding, B. Ganem and D.J. Creighton. Molecular basis of the antitumor activities of 2-crotonyloxymethyl-2-cycloalkenones. Journal of Medicinal Chemistry 46(1):194-196, 2003.
  23. Jumbe, N., A. Louie, R. Leary, W.G. Liu, M.R. Deziel, V.H. Tam, R. Bachhawat, C. Freeman, J.B. Kahn, K. Bush, M.N. Dudley, M.H. Miller and G.L. Drusano. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. Journal of Clinical Investigation 112(2):275-285, 2003
  24. Kang, W.K. and M. Weiss. Caffeine enhances myocardial uptake of idarubicin but reverses its negative inotropic effect. Naunyn-Schmiedebergs Archives of Pharmacology 367(2):151-155, 2003.
  25. Kang, W.K. and M. Weiss. Kinetic analysis of saturable myocardial uptake of idarubicin in rat heart: Effect of doxorubicin and hypothermia. Pharmaceutical Research 20(1):58-63, 2003.
  26. Kang, W.K. and M. Weiss. Modeling the metabolism of idarubicin to idarubicinol in rat heart: Effect or rutin and phenobarbital. Drug Metabolism and Disposition 31(4):462-468, 2003.
  27. Klausner, E.A., E. Lavy, D. Stepensky, E. Cserepes, M. Barta, M. Friedman and A. Hoffman. Furosemide pharmacokinetics and pharmacodynamics following gastroretentive dosage form administration to healthy volunteers. Journal of Clinical Pharmacology 43(7):711-720, 2003.
  28. Krance, R.A., I. Kuehnle, D.R. Rill, Z.Y. Mei, C. Pinetta, W. Evans, M.P. Brown, M. Pule, H.E. Heslop and M.K. Brenner. Hematopoietic and immunomodulatory effects of lytic CD45 monoclonal antibodies in patients with hematologic malignancy Biology of Blood and Marrow Transplantation 9(4):273-281, 2003.
  29. Krynetskaia, N.F., T.L. Brenner, E.Y. Krynetski, W.N. Du, J.C. Panetta, C.H. Pui and W.E. Evans. Msh2 deficiency attenuates but does not abolish thiopurine hematopoietic toxicity in Msh2(-/-) mice. Molecular Pharmacology 64(2):456-465, 2003.
  30. Kuhlmann, O., H.S. Hofmann, S.P. Muller and M. Weiss. Pharmacokinetics of idarubicin in the isolated perfused rat lung: effect of cinchonine and rutin. Anti-Cancer Drugs 14(6):411-416, 2003.
  31. Levy, G., D.E. Mager, W.K. Cheung and W. Jusko. Comparative pharmacokinetics of coumarin anticoagulants L: Physiologic modeling of S-warfarin in rats and pharmacologic target-mediated warfarin disposition in man. Journal of Pharmaceutical Sciences 92(5):985-994, 2003.
  32. Lobo, E.D. and J.P. Balthasar. Pharmacokinetic-pharmacodynamic modeling of methotrexate-induced toxicity in mice. Journal of Pharmaceutical Sciences 92(8):1654-1664, 2003
  33. Lobo, E.D., D.M. Soda and J.P. Balthasar. Application of pharmacokinetic-pharmacodynamic modeling to predict the kinetic and dynamic effects of anti–methotrexate antibodies in mice. Journal of Pharmaceutical Sciences 92(8):1665-1676, 2003.
  34. Mager, D.E., S.X. Lin, R.A. Blum, C.D. Lates and W.J. Jusko. Dose equivalency evaluation of major corticosteroids: pharmacokinetics and cell trafficking and cortisol dynamics. Journal of Clinical Pharmacology 43(11):1216-1227, 2003.
  35. Mager, D.E., M.A. Mascelli, N.S. Kleiman, D.J. Fitzgerald and D.R. Abernethy. Simultaneous modeling of abciximab plasma concentrations and ex vivo pharmacodynamics in patients undergoing coronary angioplasty. Journal of Pharmacology and Experimental Therapeutics 307(3):969-976, 2003.
  36. Mager, D.E., N. Moledina and W.J. Jusko. Relative immunosuppressive potency of therapeutic corticosteroids measured by whole blood lymphocyte proliferation. Journal of Pharmaceutical Sciences 92(7):1521-1525, 2003
  37. Mager, D.E., B. Neuteboom, C. Efthymiopoulos, A. Munafo and W.J. Jusko. Receptor-mediated pharmacokinetics and pharmacodynamics of interferon-beta 1a monkeys. Journal of Pharmacology and Experimental Therapeutics 306(1):262-270, 2003.
  38. Mager, D.E., N.A. Pyszczynski and W.J. Jusko. Integrated QSPR – Pharmacodynamic model of genomic effects of several corticosteroids. Journal of Pharmaceutical Sciences 92(4):881-889, 2003.
  39. Marier, J.F., J.L. Brazier, J. Lavigne and M.P. Ducharme. Liposomal tobramycin against pulmonary infections of Pseudomonas aeruginosa: a pharmacokinetic and efficacy study following single and multiple intratracheal administrations in rats. Journal of Antimicrobial Chemotherapy 52(2):247-252, 2003.
  40. Maring, J., H. Piersma, A. van Dalen, H.J. Groen, D.R. Uges and E.G. De Vries. Extensive hepatic replacement due to liver metastases has no effect on 5-fluorouracil pharmacokinetics. Cancer Chemotherapy and Pharmacology 51(2):167-173, 2003.
  41. Meagher, A.K., A. Forrest, C.R. Rayner, M.C. Birmingham and J.J. Schentag. Population pharmacokinetics of linezolid in patients treated in a compassionate-use program. Antimicrobial Agents and Chemotherapy 47(2):548-553, 2003.
  42. Ostergaard, D., J. Viby-Mogensen, S.N. Rasmussen, M.R. Gatke, N.A. Pedersen and L.T. Skovgaard. Pharmacokinetics and pharmacodynamics of mivacurium in patients phenotypically heterozygous for the usual and atypical plasma cholinesterase variants (UA). Acta Anaesthesiologica Scandinavica 47(10):1219-1225, 2003.
  43. Owens, T.S., H. Dodds, K. Fricke, S.K. Hanna and K.R. Crews. High-performance liquid chromatographic assay with fluorescence detection for the simultaneous measurement of carboxylate and lactone forms of irinotecan and three metabolites in human plasma. Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences 788(1):65-74, 2003.
  44. Panetta, J.C., L.C. Iacono, P.C. Adamson and C.F. Stewart. The importance of pharmacokinetic limited sampling models for childhood cancer drug development. Clinical Cancer Research 9(14):5068-5077, 2003.
  45. Panetta, J.C., M.N. Kirstein, A. Gajjar, G. Nair, M. Fouladi, R.L. Heideman, M. Wilkinson and C.F. Stewart. Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors. Cancer Chemotherapy and Pharmacology 52(6):435-441, 2003
  46. Passaro, M.D., J. Piquion, N. Mullen, D. Sutherland, S.P. Zhai, W.D. Figg, R. Blye and L.K. Nieman. Luteal phase dose-response relationships of the antiprogestin CDB-2914 in normally cycling women. Human Reproduction 18(9):1820-1827, 2003.
  47. Ramakrishnan, R., W.K. Cheung, F. Farrell, L. Joffee and W.J. Jusko. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous dose administration in cynomolgus monkeys. Journal of Pharmacology and Experimental Therapeutics 306(1):324-331, 2003.
  48. Rayner, C.R., A. Forrest, A.K. Meagher, M.C. Birmingham and J.J. Schentag. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clinical Pharmacokinetics 42(15):1411-1423, 2003.
  49. Retout, S and F. Mentre. Optimization of individual and population designs using Splus. Journal of Pharmacokinetics and Pharmacodynamics 30(6):417-443, 2003.
  50. Rowinsky, E.K., J. Rizzo, L. Ochoa, C.H. Takimoto, B. Forouzesh, G. Schwartz, L.A. Hammond, A. Patnaik, J. Kwiatek, A. Goetz, L. Denis, J. McGuire and A.W. Tolcher. A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies. Journal of Clinical Oncology 21(1):148-157, 2003.
  51. Rudek, M.A., J. Venitz, Y. Ando, E. Reed, J.M. Pluda and W.D. Figg. Factors involved in the pharmacokinetics of COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer: Clinical and experimental studies. Journal of Clinical Pharmacology 43(10):1124-1135, 2003.
  52. Santana, V.M., W.C. Zamboni, M.N. Kirstein, M. Tan, T.B. Liu, A. Gajjar, P.J. Houghton and C.F. Stewart. A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors. Clinical Cancer Research 9(2):633-640, 2003.
  53. Shimizu, M., Y. Matsumoto, M. Tatsuno and M. Fukuoka. Glucuronidation of propofol and its analogs by human and rat liver microsomes. Biological and Pharmaceutical Bulletin 26(2):216-219, 2003.
  54. Smith, P.F, B.M. Booker, P. Creaven, R. Perez and L. Pendyala. Pharmacokinetics and pharmacodynamics of mesna-mediated plasma cysteine depletion. Journal of Clinical Pharmacology 43(12):1324-1328, 2003.
  55. Smith, P.F., M.C. Birmingham, G.A. Noskin, A.K. Meagher, A. Forrest, C.R. Rayner and J.J. Schentag. Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients with neutropenia. Annals of Oncology 14(5):795-801, 2003.
  56. Sowinski, K.M., A. Lucksiri, M.B. Kays, M.K. Scott, B.A. Mueller and R.J. Hamburger. Levofloxacin pharmacokinetics in ESRD and removal by the cellulose acetate high performance-210 hemodialyzer. American Journal of Kidney Diseases 42(2):342-349, 2003.
  57. Tam, V.H., A. Louie, B.M. Lomaestro and Drusano. Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa. Pharmacotherapy 23(3):291-295, 2003.
  58. Tam, V.H., S.L. Preston and G.L. Drusano. Comparative pharmacokinetic analysis by standard two-stage method versus nonparametric population modeling. Pharmacotherapy 23(12):1545-1549, 2003.
  59. van Rossum, L.K., R.A.A. Mathot, K. Cransberg and A.G. Vulto. Optimal sampling strategies to assess inulin clearance in children by the inulin single-injection method. Clinical Chemistry 49(7):1170-1179, 2003.
  60. Wolff, A.C., R.C. Donehower, M.K. Carducci, M.A. Carducci, J.R. Brahmer, Y. Zabelina, M.O. Bradley, F.H. Anthony, C.S. Swindell, P.A. Witman, N.L. Webb and S.D. Baker. Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile. Clinical Cancer Research9(10):3589-3597 Part 1, 2003.
  61. Wong, D., R. Modi and M. Ramanathan. Assessment of Markov-dependent stochastic models for drug administration compliance. Clinical Pharmacokinetics 42(2):193-204, 2003.
  62. Xiong, H.Q., H.T. Tran, T.L. Madden, R.A. Newman and J.L. Abbruzzesse. Phase I and pharmacological study of oral 9-aminocamptothecin colloidal dispersion (NSC 603071) in patients with advanced solid tumors. Clinical Cancer Research 9(6):2066-2071, 2003.
  63. Xiong, H.Q., H.T. Tran, T.L. Madden, R.A. Newman and J.L. Abbruzzesse. Phase I and pharmacological study of oral 9-aminocamptothecin colloidal dispersion (NSC 603071) in patients with advanced solid tumors. Clinical Cancer Research 9(6):2066-2071, 2003.
  64. Xu, L., J.L. Eiseman, M.J. Egorin and D.Z. D’Argenio. Physiologically-based pharmacokinetics and molecular pharmacodynamics of 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite in tumor-bearing mice. Journal of Pharmacokinetics and Pharmacodynamics 30(3):185-219, 2003.
  65. Zhai, S.P., E.A. Sausville, A.M. Senderowicz, Y. Ando, D. Headlee, R.A. Messmann, S. Arbuck, A.J. Murgo, G. Melillo, E. Fuse and W.D. Figg. Clinical pharmacology and pharmacogenetics of flavopiridol 1-h i.v. infusion in